Archive for 2002

5 Big Drug Companies Face R&D Drought

5 Big Drug Companies Face R&D Drought Five of the world’s biggest drug companies do not have any potential billion-dollar drugs in late-stage development, highlighting the industry’s current poor R&D productivity, according to a report released on Wednesday.


Click here for reuse options!
Copyright 2002 Biotechblog

5 Big Drug Companies Face R&D Drought

5 Big Drug Companies Face R&D Drought Five of the world’s biggest drug companies do not have any potential billion-dollar drugs in late-stage development, highlighting the industry’s current poor R&D productivity, according to a report released on Wednesday.


Click here for reuse options!
Copyright 2002 Biotechblog

Informatics Moves to the Head of the Class

Informatics Moves to the Head of the Class The race is on to increase the quantity and quality of bio-IT training programs as government and academia bet the need will be great. Will the job market back that up?


Click here for reuse options!
Copyright 2002 Biotechblog

Nanopharmaceuticals Open Up Brand New Field Of Study

Nanopharmaceuticals Open Up Brand New Field Of Study Drug-binding molecules tiny enough to travel through the body’s smallest capillaries may provide a way to spare the heart and other organs from the toxic effects of drug overdose.


Click here for reuse options!
Copyright 2002 Biotechblog

Networked Pharma

Networked Pharma The pharmaceutical industry is experiencing a deepening productivity crisis. The industry’s preferred escape mechanism from this predicament has been to increase investment in current business activities – primarily R&D and sales – to sustain productivity levels or, ideally, to exploit economies of scale. This has been implemented through organic growth of critical resources […]


Click here for reuse options!
Copyright 2002 Biotechblog

Pharma Financial Squeeze Bodes Ill for Genomics

Pharma Financial Squeeze Bodes Ill for Genomics ‘Caution: Tougher Times Ahead’ may be an apt sign for biotech in general and genomics in particular, according to a panel of leading venture capitalists.


Click here for reuse options!
Copyright 2002 Biotechblog

DeCode's Genetic Breakthrough Barely Registers

DeCode’s Genetic Breakthrough Barely Registers DeCode Genetics published an important genetic map–assembled by methods very different from those used to create the sequence of the human genome–that will make it much easier for scientists to hunt down new genes linked to disease. But DeCode’s stock continues to languish.


Click here for reuse options!
Copyright 2002 Biotechblog

DeCode’s Genetic Breakthrough Barely Registers

DeCode’s Genetic Breakthrough Barely Registers DeCode Genetics published an important genetic map–assembled by methods very different from those used to create the sequence of the human genome–that will make it much easier for scientists to hunt down new genes linked to disease. But DeCode’s stock continues to languish.


Click here for reuse options!
Copyright 2002 Biotechblog

Celera abandons gene sequencing

Celera abandons gene sequencing The company that shared the glory for unravelling the code of life of human beings has turned its back on gene sequencing. Celera Genomics of Rockville, Maryland, announced this week that it is to develop drugs instead


Click here for reuse options!
Copyright 2002 Biotechblog

%d bloggers like this: